LC
ALLO icon

Lindbrook Capital’s Allogene Therapeutics ALLO Stock Holding History

Lindbrook Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$5.44K Buy
3,729
+3,720
+41,333% +$7.01K ﹤0.01% 1917
2024
Q4 		$19 Buy
+9
New +$22 ﹤0.01% 2763
2024
Q3 		– Sell
-117
Closed -$273 – 2825
2024
Q2 		$273 Sell
117
-1,132
-91% -$3.34K ﹤0.01% 2685
2024
Q1 		$5.58K Sell
1,249
-348
-22% -$1.45K ﹤0.01% 1849
2023
Q4 		$5.13K Buy
1,597
+949
+146% +$2.69K ﹤0.01% 1872
2023
Q3 		$2.05K Sell
648
-725
-53% -$3.18K ﹤0.01% 2118
2023
Q2 		$6.82K Sell
1,373
-354
-20% -$1.92K ﹤0.01% 1660
2023
Q1 		$8.53K Buy
+1,727
New +$11.1K ﹤0.01% 1550
2022
Q4 		– Sell
-418
Closed -$3.87K – 2828
2022
Q3 		$5K Sell
418
-18
-4% -$245 ﹤0.01% 1630
2022
Q2 		$5K Buy
436
+326
+296% +$2.89K ﹤0.01% 1518
2022
Q1 		$1K Buy
+110
New +$1.15K ﹤0.01% 2150

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Lindbrook Capital's ALLO Position: Q1 2025 in Review

Lindbrook Capital increased its Allogene Therapeutics (ALLO) stake by 41,333% in Q1 2025, buying an estimated $7.01K and bringing the position to 3,729 shares worth $5.44K. The position accounts for ﹤0.01% of the portfolio, ranked #1917.

Lindbrook Capital first reported a position in ALLO in Q1 2022 and has held it in 11 quarters since. The position peaked at $8.53K in Q1 2023. 170 funds tracked by Wall St. Rank hold ALLO as of Q1 2025.

  • Lindbrook Capital held 3,729 shares of Allogene Therapeutics worth $5.44K as of Q1 2025.
  • Lindbrook Capital bought 3,720 Allogene Therapeutics shares in Q1 2025, an estimated $7.01K.
  • Allogene Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1917 holding.
  • Lindbrook Capital first reported a position in Allogene Therapeutics in Q1 2022 and has held it in 11 quarters since.
  • Lindbrook Capital's Allogene Therapeutics position peaked at $8.53K in Q1 2023.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.